Week In Review: Fosun Signs $840 Million Deal For U.S. Rights To Henlius' PD-1
Shanghai Fosun Pharma announced it has licensed US rights to a PD-1 candidate from its longstanding partner Henlius Biotech in an $840 million agreement. Read more here...
Source: seekingalpha.com